Diffusion-weighted magnetic resonance imaging in patients with prostate cancer treated with radiotherapy

Tumori

Volumn 102, Issue 1, 2016, Pages 71-76

  Iannelli, Giancarlo ^a   Caivano, Rocchina ^a   Rago, Luciana ^a   Simeon, Vittorio ^a   Lotumolo, Antonella ^a   Rabasco, Paola ^a   Villonio, Antonio ^a   Gioioso, Matilde ^a   Mastrangelo, Pietro ^a   Barchetti, Flavio ^b   Panebianco, Valeria ^b   Macarini, Luca ^c   Guglielmi, Giuseppe ^c,d   Cammarota, Aldo ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Apparent diffusion coefficient; Diffusion weighed imaging; Magnetic resonance imaging; Prostate cancer; Response to therapy

Indexed keywords

AGED; AREA UNDER THE CURVE; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; HUMAN; IMAGE ANALYSIS; MALE; MORBIDITY; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; RECEIVER OPERATING CHARACTERISTIC; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT RESPONSE; VERY ELDERLY; ADENOCARCINOMA; BLOOD; CANCER GRADING; FEASIBILITY STUDY; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; REPRODUCIBILITY; SAMPLE SIZE; TREATMENT OUTCOME;

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; DIFFUSION MAGNETIC RESONANCE IMAGING; FEASIBILITY STUDIES; HUMANS; MALE; NEOPLASM GRADING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 84962822406     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.5301/tj.5000415     Document Type: Article

References (30)

1. Kundra V, Silverman PM, Matin S.F., Choi H. Imaging in oncology from the University of Texas M.D. Anderson Cancer Center: diagnosis, staging, and surveillance of prostate cancer. AJR Am J Roentgenol. 2007; 189(4):830-844.
2. Steinberg GD, Carter BS, Beaty T.H., Childs B., Walsh PC. Family history and the risk of prostate cancer. Prostate. 1990; 17(4): 337-347.
3. Schröder F.H., Hugosson J, Roobol M.J., et al; ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012; 366(11):981-990.
4. Kelloff GJ, Choyke P, Coffey DS; Prostate Cancer Imaging Working Group. Challenges in clinical prostate cancer: role of imaging. AJR Am J Roentgenol. 2009; 192(6):1455-1470.
5. Lawrentschuk N, Fleshner N. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int. 2009; 103(6):730-733.
6. Kurhanewicz J, Vigneron D, Carroll P., Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol. 2008; 18(1):71-77.
7. Engelbrecht MR, Jager GJ, Laheij R.J., Verbeek AL, van Lier HJ, Barentsz JO. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol. 2002; 12(9): 2294-2302.
8. Caivano R, Cirillo P, Balestra A., et al. Prostate cancer in magnetic resonance imaging: diagnostic utilities of spectroscopic sequences. J Med Imaging Radiat Oncol. 2012; 56(6): 606-616.
9. Yamamura J, Salomon G, Buchert R., et al. MR imaging of prostate cancer: diffusion weighted imaging and (3D) hydrogen 1 (1H) MR spectroscopy in comparison with histology radiology research and practice volume. Radiol Res Pract. 2011; 2011:616852.
10. Caivano R, Rabasco P, Lotumolo A., et al. Comparison between Gleason score and apparent diffusion coefficient obtained from diffusion-weighted imaging of prostate cancer patients. Cancer Invest. 2013; 31(9):625-629.
11. Takayama Y, Kishimoto R, Hanaoka S., et al. ADC value and diffusion tensor imaging of prostate cancer: changes in carbon-ion radiotherapy. J Magn Reson Imaging. 2008; 27(6):1331-1335.
12. Park SY, Kim CK, Park B.K., et al. Early changes in apparent diffusion coefficient from diffusion-weighted MR imaging during radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 83(2):749-755.
13. Song I, Kim CK, Park B.K., Park W Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. AJR Am J Roentgenol. 2010; 194(6):W477-82.
14. Iraha Y, Murayama S, Kamiya A., Iraha S, Ogawa K. Diffusion-weighted MRI and PSA correlations in patients with prostate cancer treated with radiation and hormonal therapy. Anticancer Res. 2012; 32(10):4467-4471.
15. Hricak H, Choyke PL, Eberhardt S.C., Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology. 2007; 243(1):28-53.
16. Vicini FA, Vargas C, Abner A., Kestin L, Horwitz E, Martinez A. Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. J Urol. 2005; 173(5):1456-1462.
17. Ohgiya Y, Suyama J, Seino N., et al. Diagnostic accuracy of ultra-high-b-value 3.0-T diffusion-weighted MR imaging for detection of prostate cancer. Clin Imaging. 2012; 36(5):526-531.
18. 2). J Magn Reson Imaging. 2012; 36(1):198-205.
19. 2 for tumor conspicuity and discrimination of aggressiveness. PLoS ONE. 2014; 9(5): e96619.
20. Ueno Y, Kitajima K, Sugimura K., et al. Ultra-high b-value diffusion-weighted MRI for the detection of prostate cancer with 3-T MRI. J Magn Reson Imaging. 2013; 38(1):154-160.
21. Katahira K, Takahara T, Kwee T.C., et al. Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation. Eur Radiol. 2011; 21(1):188-196.
22. Woodfield CA, Tung GA, Grand D.J., Pezzullo JA, Machan JT, Renzulli JF II. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol. 2010; 194(4):W316-22.
23. Kim CK, Park BK Update of prostate magnetic resonance imaging at 3 T. J Comput Assist Tomogr. 2008; 32(2):163-172.
24. Engelbrecht MR, Puech P, Colin P., Akin O, Lemaître L, Villers A. Multimodality magnetic resonance imaging of prostate cancer. J Endourol. 2010; 24(5):677-684.
25. Pickles MD, Gibbs P, Lowry M., Turnbull LW Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging. 2006; 24(7):843-847.
26. DeVries AF, Kremser C, Hein P.A., et al. Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys. 2003; 56(4):958-965.
27. Moffat BA, Chenevert TL, Lawrence T.S., et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA. 2005; 102(15):5524-5529.
28. Hamstra DA, Chenevert TL, Moffat B.A., et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci USA. 2005; 102(46):16759-16764.
29. Chen CY, Li CW, Kuo Y.T., et al. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants: initial experience. Radiology. 2006; 239(2):448-456.
30. Petraki CD, Sfikas CP Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. Histol Histopathol. 2007; 22(1):107-118.